Japan Self-Monitoring Blood Glucose Devices Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Historical Data Period | 2021 - 2025 |
| Base Year Market Size (2026) | USD 0.74 Billion |
| Market Size (2027) | USD 0.78 Billion |
| Market Size (2032) | USD 1.03 Billion |
| Growth Rate (2027 - 2032) | 5.63 % |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Japan Self-Monitoring Blood Glucose Devices Market Analysis by Mordor Intelligence
The Japan Self-Monitoring Blood Glucose Devices Market size was valued at USD 0.74 billion in 2026 and is estimated to grow from USD 0.78 billion in 2027 to reach USD 1.03 billion by 2032, at a CAGR of 5.63% during the forecast period (2027-2032).
Routine blood glucose monitoring enables patients to track changes in their glucose levels and make informed decisions regarding their daily health habits. The readings provide actionable insights that can support adjustments in diet, physical activity, and treatment adherence. Prolonged high blood glucose levels in people with diabetes can lead to serious complications, including kidney dysfunction, nerve damage, and vision-related disorders. Therefore, regular and accurate monitoring supports the timely management of abnormal glucose levels and helps reduce the risk of diabetes-related complications.
In Japan, increasing emphasis on diabetes self-care and the adoption of advanced monitoring technologies are driving demand for self-monitoring blood glucose devices. The country’s growing elderly population, which faces a higher risk of diabetes and related complications, further supports the need for regular glucose monitoring. Additionally, the availability of compact, user-friendly devices and digital health platforms is expected to encourage greater patient adherence and support the growth of the Japan self-monitoring blood glucose devices market.
Digital health applications that capture and summarize blood glucose readings, insulin doses, food intake, and physical activity can enhance diabetes self-management. These solutions can reduce the overall disease burden and improve diabetes care. Moreover, the integration of blood glucose monitoring devices with insulin dose calculators, automated insulin titration software, and remote coaching tools offers added support for patients with poorly controlled diabetes. Such technological advancements can improve key clinical outcomes and contribute to market growth over the coming years.
The World Health Assembly Resolution recommends integrating diabetes prevention and treatment into primary healthcare services, establishing pathways to substantially expand access to insulin, promoting the convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and strengthening diabetes monitoring and surveillance. It also calls on the WHO to advise Member States to ensure uninterrupted treatment for people living with diabetes during humanitarian emergencies. This milestone provides a global mandate for diabetes-related initiatives over the next decade.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Japan Self-Monitoring Blood Glucose Devices Market Trends and Insights
Rising Diabetes Prevalence in Japan
The diabetes population in Japan is expected to grow by about 0.30% over the forecast period.
Diabetes has emerged as a global epidemic. Japan had around 11 million people with diabetes, according to IDF data. Japan has one of the largest elderly populations in the world, which is more susceptible to the onset of type-2 diabetes. As Japan's population continues to age, the prevalence of diabetes increases as well. The monitoring and management of blood glucose levels are on the rise to avoid negative consequences such as cardiovascular diseases, kidney disorders, and many other conditions.
Diabetes mellitus has been of wide concern with its high prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. The Japanese healthcare system has a few disease management programs conducted by the Japan Association for Diabetes Education and Care. Japan is one of the regional leaders in the Asia-Pacific in terms of diabetic public health policies. The country promotes public awareness and embraces preventive policies that focus on lifestyle and dietary adjustments, which can lessen the likelihood of adult-onset diabetes.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
The Test Strips Segment holds the highest market share in the current year
The test strip segment held the highest market share of about 70% in the current year.
Blood glucose test strips are small, disposable strips and are a key component of blood glucose testing. When blood is placed on the test strip, it reacts with a chemical called glucose oxidase, producing gluconic acid from the glucose in the blood. At the other end of the test strip, the meter transfers a current to the strip. The test strip has electric terminals, which allow the meter to measure the current between the terminals. The current between the terminals changes depending on the level of gluconic acid that has been produced. The blood glucose meter then uses an algorithm to work out the blood glucose level based on the difference in current.
The growth in market share of test strips is expected to be higher than that of glucose meters because of the difference in use-case frequency. The glucometer is a one-time purchase; test strips, on the other hand, are a continuous investment as a test strip needs to be disposed of after one use, causing a recurrent cost impact. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost during the same time frame,
Diabetes has been identified as a healthcare priority by the Ministry of Health, Labour, and Welfare. The high prevalence of type-2 diabetes is associated with a significant economic burden. The costs of diabetes are increased in patients with comorbidities such as hypertension and hyperlipidemia and in patients who develop complications. Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and diabetics can visit doctors freely in Japan.
Such advantages will help increase the adoption of these products in the Japanese market.
Competitive Landscape
The Japanese self-monitoring blood glucose device market is fragmented, with a few significant and other generic players. Manufacturers like Abbott, LifeScan, Roche, Ascensia, etc. occupy a major share.
Japan Self-Monitoring Blood Glucose Devices Industry Leaders
-
Roche Diabetes Care
-
Abbott Diabetes Care
-
LifeScan
-
Nipro
-
Arkray
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- March 2023: Astellas Pharma announced that it entered into an agreement with Roche Diabetes Care Japan for the development and commercialization of Roche Diabetes Care's Accu-Chek Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar. BlueStar is an FDA-cleared digital health solution for diabetes patients developed by Welldoc and currently marketed in the U.S. and Canada. Astellas and Welldoc are jointly developing BlueStar in Japan. In the future, Astellas is expected to obtain regulatory approval and reimbursement as a combined medical product.
- March 2022: Quantum Operation Inc., a Tokyo-based healthcare IoT startup, presented the world's first non-invasive glucose monitor capable of continuous measurement. It measures the blood sugar from the wrist without any pricks.
Japan Self-Monitoring Blood Glucose Devices Market Report Scope
Self-monitoring of blood glucose is an approach used by diabetic patients to measure their blood sugar level themselves using a glucometer, test strips, and lancets. Based on the readings, patients can adjust or check the effect of their treatment. The Japanese self-monitoring blood glucose device market is segmented by components. The report offers the value (in USD) and volume (in units) for the above segments.
| Glucometer Devices |
| Test Strips |
| Lancets |
| Component | Glucometer Devices |
| Test Strips | |
| Lancets |
Key Questions Answered in the Report
How big is the Japan Self-Monitoring Blood Glucose Devices Market?
The Japan Self-Monitoring Blood Glucose Devices Market size is expected to reach USD 0.78 billion in 2027 and grow at a CAGR of 5.63% to reach USD 1.03 billion by 2032.
What is the current Japan Self-Monitoring Blood Glucose Devices Market size?
In 2026, the Japan Self-Monitoring Blood Glucose Devices Market size is expected to reach USD 0.74 billion.
Who are the key players in Japan Self-Monitoring Blood Glucose Devices Market?
Roche Diabetes Care, Abbott Diabetes Care, LifeScan, Nipro and Arkray are the major companies operating in the Japan Self-Monitoring Blood Glucose Devices Market.
What years does this Japan Self-Monitoring Blood Glucose Devices Market cover, and what was the market size in 2025?
In 2025, the Japan Self-Monitoring Blood Glucose Devices Market size was estimated at USD 0.70 billion. The report covers the Japan Self-Monitoring Blood Glucose Devices Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the Japan Self-Monitoring Blood Glucose Devices Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.